Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats.

Ozten N, Vega K, Liehr J, Huang X, Horton L, Cavalieri EL, Rogan EG, Bosland MC.

Horm Cancer. 2019 Jun;10(2-3):77-88. doi: 10.1007/s12672-019-00360-7. Epub 2019 Mar 16.

PMID:
30877616
2.

Estrogen Metabolism in African-American Women with and without Breast Cancer: A Pilot Study.

Zahid M, Mondal B, LeVan TD, Rogan EG.

Chem Res Toxicol. 2019 Jan 22;32(1):190-194. doi: 10.1021/acs.chemrestox.8b00285. Epub 2018 Dec 28.

PMID:
30525503
3.

Modulation of Cellular Response to Arsenic Trioxide Toxicity by Resveratrol.

Mondal B, Chen H, Wen W, Cavalieri EL, Rogan EG, Zahid M.

ACS Omega. 2018 May 31;3(5):5511-5515. doi: 10.1021/acsomega.7b01727. Epub 2018 May 21.

4.

The Fate of Synthetic and Endogenous Hormones Used in the US Beef and Dairy Industries and the Potential for Human Exposure.

Kolok AS, Ali JM, Rogan EG, Bartelt-Hunt SL.

Curr Environ Health Rep. 2018 Jun;5(2):225-232. doi: 10.1007/s40572-018-0197-9. Review.

PMID:
29754262
5.

Critical depurinating DNA adducts: Estrogen adducts in the etiology and prevention of cancer and dopamine adducts in the etiology and prevention of Parkinson's disease.

Cavalieri EL, Rogan EG, Zahid M.

Int J Cancer. 2017 Sep 15;141(6):1078-1090. doi: 10.1002/ijc.30728. Epub 2017 Apr 24. Review.

6.

Etiology and prevention of prevalent types of cancer.

Cavalieri EL, Rogan EG.

J Rare Dis Res Treat. 2017;2(3):22-29. doi: 10.29245/2572-9411/2017/3.1093. Epub 2017 May 2.

7.

Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention.

Cavalieri EL, Rogan EG.

Clin Transl Med. 2016 Mar;5(1):12. doi: 10.1186/s40169-016-0088-3. Epub 2016 Mar 15. Review.

8.

IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.

Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, Jiang B, Rohr J, Cannon A, Steidl C, Fu K, Li Y, Hung S, Weisenburger DD, Greiner TC, Smith L, Ott G, Rogan EG, Staudt LM, Vose J, Iqbal J, Chan WC.

Blood. 2015 Oct 8;126(15):1741-52. doi: 10.1182/blood-2015-05-644591. Epub 2015 Aug 12.

9.

Breast health and reducing breast cancer risk: a functional medicine approach.

Muran PJ, Muran SY, Beseler CL, Cavalieri EL, Rogan EG, Zahid M.

J Altern Complement Med. 2015 Jun;21(6):321-6. doi: 10.1089/acm.2014.0365. Epub 2015 May 14.

PMID:
25974761
10.

Associations between Dietary Intake of Fruits and Vegetables in relation to Urinary Estrogen DNA Adduct Ratio.

Reding KW, Zahid M, Cavalieri E, Rogan EG, Raccor BS, Atkinson C, Yong M, Newton KM, Lampe JW.

Open J Prev Med. 2014 Jun;4(6):429-437.

11.

Unbalanced estrogen metabolism in ovarian cancer.

Zahid M, Beseler CL, Hall JB, LeVan T, Cavalieri EL, Rogan EG.

Int J Cancer. 2014 May 15;134(10):2414-23. doi: 10.1002/ijc.28565. Epub 2014 Jan 25.

12.

Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells.

Yang L, Zahid M, Liao Y, Rogan EG, Cavalieri EL, Davidson NE, Yager JD, Visvanathan K, Groopman JD, Kensler TW.

Carcinogenesis. 2013 Nov;34(11):2587-92. doi: 10.1093/carcin/bgt246. Epub 2013 Jul 10.

13.

Unbalanced estrogen metabolism in thyroid cancer.

Zahid M, Goldner W, Beseler CL, Rogan EG, Cavalieri EL.

Int J Cancer. 2013 Dec 1;133(11):2642-9. doi: 10.1002/ijc.28275. Epub 2013 Jun 14.

14.

Preface.

Cavalieri E, Rogan EG.

Drug Discov Today Dis Mech. 2012 Summer;9(1-2):e1-e3. Epub 2012 Dec 22. No abstract available.

15.

The etiology and prevention of breast cancer.

Cavalieri EL, Rogan EG.

Drug Discov Today Dis Mech. 2012 Summer;9(1-2):e55-e69.

16.

Evaluation of serum estrogen-DNA adducts as potential biomarkers for breast cancer risk.

Pruthi S, Yang L, Sandhu NP, Ingle JN, Beseler CL, Suman VJ, Cavalieri EL, Rogan EG.

J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):73-9. doi: 10.1016/j.jsbmb.2012.02.002. Epub 2012 Feb 24.

17.

Formation of diethylstilbestrol-DNA adducts in human breast epithelial cells and inhibition by resveratrol.

Hinrichs B, Zahid M, Saeed M, Ali MF, Cavalieri EL, Rogan EG.

J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):276-81. doi: 10.1016/j.jsbmb.2011.08.009. Epub 2011 Aug 26.

18.

Imbalanced estrogen metabolism in the brain: possible relevance to the etiology of Parkinson's disease.

Gaikwad NW, Murman D, Beseler CL, Zahid M, Rogan EG, Cavalieri EL.

Biomarkers. 2011 Aug;16(5):434-44. doi: 10.3109/1354750X.2011.588725. Epub 2011 Jun 21.

19.

Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer.

Cavalieri EL, Rogan EG.

J Steroid Biochem Mol Biol. 2011 Jul;125(3-5):169-80. doi: 10.1016/j.jsbmb.2011.03.008. Epub 2011 Mar 21. Review.

20.

Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland.

Kim T, Park H, Yue W, Wang JP, Atkins KA, Zhang Z, Rogan EG, Cavalieri EL, Mohammad KS, Kim S, Santen RJ, Aiyar SE.

Breast Cancer Res Treat. 2011 Apr;126(3):779-89. doi: 10.1007/s10549-010-1301-5. Epub 2010 Dec 18.

21.

Is bisphenol A a weak carcinogen like the natural estrogens and diethylstilbestrol?

Cavalieri EL, Rogan EG.

IUBMB Life. 2010 Oct;62(10):746-51. doi: 10.1002/iub.376.

22.

Resveratrol and N-acetylcysteine block the cancer-initiating step in MCF-10F cells.

Zahid M, Saeed M, Beseler C, Rogan EG, Cavalieri EL.

Free Radic Biol Med. 2011 Jan 1;50(1):78-85. doi: 10.1016/j.freeradbiomed.2010.10.662. Epub 2010 Oct 8.

23.

N-acetylcysteine blocks formation of cancer-initiating estrogen-DNA adducts in cells.

Zahid M, Saeed M, Ali MF, Rogan EG, Cavalieri EL.

Free Radic Biol Med. 2010 Aug 1;49(3):392-400. doi: 10.1016/j.freeradbiomed.2010.04.028. Epub 2010 May 31.

24.

Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers.

Cavalieri EL, Rogan EG.

Future Oncol. 2010 Jan;6(1):75-91. doi: 10.2217/fon.09.137. Review.

25.

Benzene and dopamine catechol quinones could initiate cancer or neurogenic disease.

Zahid M, Saeed M, Rogan EG, Cavalieri EL.

Free Radic Biol Med. 2010 Jan 15;48(2):318-24. doi: 10.1016/j.freeradbiomed.2009.11.002. Epub 2009 Nov 10.

26.

Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma.

Gaikwad NW, Yang L, Weisenburger DD, Vose J, Beseler C, Rogan EG, Cavalieri EL.

Biomarkers. 2009 Nov;14(7):502-12. doi: 10.3109/13547500903121715.

27.

NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells.

Singh S, Zahid M, Saeed M, Gaikwad NW, Meza JL, Cavalieri EL, Rogan EG, Chakravarti D.

J Steroid Biochem Mol Biol. 2009 Oct;117(1-3):56-66. doi: 10.1016/j.jsbmb.2009.07.003. Epub 2009 Jul 21.

28.

Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells.

Lu F, Zahid M, Wang C, Saeed M, Cavalieri EL, Rogan EG.

Cancer Prev Res (Phila). 2008 Jul;1(2):135-45. doi: 10.1158/1940-6207.CAPR-08-0037.

29.

Urine biomarkers of risk in the molecular etiology of breast cancer.

Gaikwad NW, Yang L, Pruthi S, Ingle JN, Sandhu N, Rogan EG, Cavalieri EL.

Breast Cancer (Auckl). 2009 Jan 6;3:1-8.

30.

Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones.

Gaikwad NW, Yang L, Rogan EG, Cavalieri EL.

Free Radic Biol Med. 2009 Jan 15;46(2):253-62. doi: 10.1016/j.freeradbiomed.2008.10.029. Epub 2008 Nov 1.

31.

Novel biomarkers for risk of prostate cancer: results from a case-control study.

Yang L, Gaikwad NW, Meza J, Cavalieri EL, Muti P, Trock B, Rogan EG.

Prostate. 2009 Jan 1;69(1):41-8. doi: 10.1002/pros.20850.

32.

hPMC2 is required for recruiting an ERbeta coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen.

Sripathy SP, Chaplin LJ, Gaikwad NW, Rogan EG, Montano MM.

Oncogene. 2008 Oct 23;27(49):6376-84. doi: 10.1038/onc.2008.235. Epub 2008 Jul 28.

33.

Prevention of estrogen-DNA adduct formation in MCF-10F cells by resveratrol.

Zahid M, Gaikwad NW, Ali MF, Lu F, Saeed M, Yang L, Rogan EG, Cavalieri EL.

Free Radic Biol Med. 2008 Jul 15;45(2):136-45. doi: 10.1016/j.freeradbiomed.2008.03.017. Epub 2008 Apr 8.

34.

Prevalence of BER gene polymorphisms in sporadic breast cancer.

Ali MF, Meza JL, Rogan EG, Chakravarti D.

Oncol Rep. 2008 Apr;19(4):1033-8.

PMID:
18357393
35.

Reduction of estrogen-induced transformation of mouse mammary epithelial cells by N-acetylcysteine.

Venugopal D, Zahid M, Mailander PC, Meza JL, Rogan EG, Cavalieri EL, Chakravarti D.

J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):22-30. doi: 10.1016/j.jsbmb.2007.12.003. Epub 2007 Dec 7.

36.

The molecular etiology of breast cancer: evidence from biomarkers of risk.

Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, Rogan EG, Cavalieri EL.

Int J Cancer. 2008 May 1;122(9):1949-57.

37.

Inhibition of depurinating estrogen-DNA adduct formation by natural compounds.

Zahid M, Gaikwad NW, Rogan EG, Cavalieri EL.

Chem Res Toxicol. 2007 Dec;20(12):1947-53. Epub 2007 Nov 27.

PMID:
18039013
38.

The role of polycyclic aromatic hydrocarbon-DNA adducts in inducing mutations in mouse skin.

Chakravarti D, Venugopal D, Mailander PC, Meza JL, Higginbotham S, Cavalieri EL, Rogan EG.

Mutat Res. 2008 Jan 8;649(1-2):161-78. Epub 2007 Sep 7.

39.

Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones.

Gaikwad NW, Rogan EG, Cavalieri EL.

Free Radic Biol Med. 2007 Nov 1;43(9):1289-98. Epub 2007 Aug 3.

40.
41.

Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA.

Zhang Y, Gaikwad NW, Olson K, Zahid M, Cavalieri EL, Rogan EG.

Metabolism. 2007 Jul;56(7):887-94.

PMID:
17570247
42.

Ortho-quinones of benzene and estrogens induce hyperproliferation of human peripheral blood mononuclear cells.

Chakravarti D, Zahid M, Backora M, Myers EM, Gaikwad N, Weisenburger DD, Cavalieri EL, Rogan EG, Joshi SS.

Leuk Lymphoma. 2006 Dec;47(12):2635-44.

PMID:
17169809
43.

Potential biomarker for early risk assessment of prostate cancer.

Markushin Y, Gaikwad N, Zhang H, Kapke P, Rogan EG, Cavalieri EL, Trock BJ, Pavlovich C, Jankowiak R.

Prostate. 2006 Oct 1;66(14):1565-71.

PMID:
16894534
44.
45.

Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB rat2 embryonic cells, and the mutational spectrum of 4-hydroxyestradiol.

Zhao Z, Kosinska W, Khmelnitsky M, Cavalieri EL, Rogan EG, Chakravarti D, Sacks PG, Guttenplan JB.

Chem Res Toxicol. 2006 Mar;19(3):475-9.

PMID:
16544955
46.

Development of monoclonal antibodies to 4-hydroxyestrogen-2-N-acetylcysteine conjugates: immunoaffinity and spectroscopic studies.

Markushin Y, Kapke P, Saeed M, Zhang H, Dawoud A, Rogan EG, Cavalieri EL, Jankowiak R.

Chem Res Toxicol. 2005 Oct;18(10):1520-7.

PMID:
16533015
47.

Improved measurement of dibenzo[a,l]pyrene-induced abasic sites by the aldehyde-reactive probe assay.

Chakravarti D, Badawi AF, Venugopal D, Meza JL, Crandall LZ, Rogan EG, Cavalieri EL.

Mutat Res. 2005 Dec 30;588(2):158-65. Epub 2005 Nov 17.

PMID:
16298157
48.

Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma.

Singh S, Chakravarti D, Edney JA, Hollins RR, Johnson PJ, West WW, Higginbotham SM, Cavalieri EL, Rogan EG.

Oncol Rep. 2005 Oct;14(4):1091-6.

PMID:
16142378
49.

Identification and quantification of the depurinating DNA adducts formed in mouse skin treated with dibenzo[a,l]pyrene (DB[a,l]P) or its metabolites and in rat mammary gland treated with DB[a,l]P.

Cavalieri EL, Rogan EG, Li KM, Todorovic R, Ariese F, Jankowiak R, Grubor N, Small GJ.

Chem Res Toxicol. 2005 Jun;18(6):976-83.

PMID:
15962932
50.

A unifying mechanism in the initiation of cancer and other diseases by catechol quinones.

Cavalieri EL, Rogan EG.

Ann N Y Acad Sci. 2004 Dec;1028:247-57. Review.

PMID:
15650250

Supplemental Content

Loading ...
Support Center